| Name | Title | Contact Details |
|---|---|---|
Colin Harman |
Head of Technology | Profile |
Sales Impact Academy is the worlds leading go-to-market learning platform providing a continuous live learning solution for high-growth technology companies.
Skillshare is an online learning community with thousands of classes in design, business, technology and more. Anyone can join the millions of members in our community to learn cutting-edge skills, network with peers and discover new opportunities.
Health e(fx) helps employers, advisors and TPAs stay a step ahead of changing healthcare compliance and reporting requirements. Visit: https://t.co/sqfiamVt3j
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.